Clinical trial
A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
NCT05181540 is registered in ClinicalTrials.gov with Angiocrine Bioscience as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of AB-205 Plus Standard of Care Versus Placebo Plus Standard of Care in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) (E-CELERATE)
- Lead sponsor
- Angiocrine Bioscience
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- February 21, 2022
- Completion date
- January 31, 2025
- Enrollment
- 130 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.
hodgkin lymphoma, non hodgkin lymphoma